|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 2/23/17 Pfizer Inc 10-K 12/31/16 168:37M |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 504K
2: EX-10.4 Form of Stock Option Grant Notice and Summary of HTML 94K
Key Terms
4: EX-13 2016 Financial Report HTML 2.85M
5: EX-21 Subsidiaries of the Company HTML 150K
6: EX-23 Consent of Kpmg, Independent Registered Public HTML 63K
Accounting Firm
3: EX-12 Computation of Ratio of Earnings to Fixed Charges HTML 81K
7: EX-31.1 Certification by the Chief Executive Officer - 302 HTML 58K
8: EX-31.2 Certification by the Chief Financial Officer - 302 HTML 58K
9: EX-32.1 Certification by the Chief Executive Officer - 906 HTML 55K
10: EX-32.2 Certification by the Chief Financial Officer - 906 HTML 55K
17: R1 Document and Entity Information HTML 82K
18: R2 Consolidated Statements of Income HTML 146K
19: R3 Consolidated Statements of Comprehensive Income HTML 139K
20: R4 Consolidated Balance Sheets HTML 173K
21: R5 Consolidated Balance Sheets (Parenthetical) HTML 72K
22: R6 Consolidated Statements of Equity HTML 138K
23: R7 Consolidated Statements of Equity (Parenthetical) HTML 56K
24: R8 Consolidated Statements of Cash Flows HTML 196K
25: R9 Consolidated Statements of Cash Flows HTML 57K
(Parenthetical)
26: R10 Basis of Presentation and Significant Accounting HTML 143K
Policies
27: R11 Acquisitions, Assets and Liabilities Held for HTML 256K
Sale, Licensing Agreements, Research and
Development and Collaborative Arrangements,
Equity-Method Investments and Cost-Method
Investment
28: R12 Restructuring Charges and Other Costs Associated HTML 152K
with Acquisitions and Cost-Reduction/Productivity
Initiatives
29: R13 Other (Income)/Deductions - Net HTML 137K
30: R14 Tax Matters HTML 296K
31: R15 Accumulated Other Comprehensive Loss, Excluding HTML 102K
Noncontrolling Interests
32: R16 Financial Instruments HTML 398K
33: R17 Inventories HTML 69K
34: R18 Property, Plant and Equipment HTML 77K
35: R19 Identifiable Intangible Assets and Goodwill HTML 167K
36: R20 Pension and Postretirement Benefit Plans and HTML 907K
Defined Contribution Plans
37: R21 Equity HTML 84K
38: R22 Share-Based Payments HTML 295K
39: R23 Earnings Per Common Share Attributable to Pfizer HTML 106K
Inc. Common Shareholders
40: R24 Lease Commitments HTML 69K
41: R25 Insurance HTML 55K
42: R26 Commitments and Contingencies HTML 147K
43: R27 Segment, Geographic and Other Revenue Information HTML 422K
44: R28 Subsequent Event HTML 57K
45: R29 Basis of Presentation and Significant Accounting HTML 198K
Policies (Policies)
46: R30 Acquisitions, Assets and Liabilities Held for HTML 180K
Sale, Licensing Agreements, Research and
Development and Collaborative Arrangements,
Equity-Method Investments and Cost-Method
Investment (Tables)
47: R31 Restructuring Charges and Other Costs Associated HTML 147K
with Acquisitions and Cost-Reduction/Productivity
Initiatives (Tables)
48: R32 Other (Income)/Deductions - Net (Tables) HTML 139K
49: R33 Tax Matters (Tables) HTML 271K
50: R34 Accumulated Other Comprehensive Loss, Excluding HTML 98K
Noncontrolling Interests (Tables)
51: R35 Financial Instruments (Tables) HTML 390K
52: R36 Inventories (Tables) HTML 88K
53: R37 Property, Plant and Equipment (Tables) HTML 76K
54: R38 Identifiable Intangible Assets and Goodwill HTML 231K
(Tables)
55: R39 Pension and Postretirement Benefit Plans and HTML 956K
Defined Contribution Plans (Tables)
56: R40 Equity (Tables) HTML 66K
57: R41 Share-Based Payments (Tables) HTML 309K
58: R42 Earnings Per Common Share Attributable to Pfizer HTML 104K
Inc. Common Shareholders (Tables)
59: R43 Lease Commitments (Tables) HTML 66K
60: R44 Segment, Geographic and Other Revenue Information HTML 579K
(Tables)
61: R45 Basis of Presentation and Significant Accounting HTML 160K
Policies (Details)
62: R46 Acquisitions, Assets and Liabilities Held for HTML 92K
Sale, Licensing Agreements, Research and
Development and Collaborative Arrangements,
Equity-Method Investments and Cost-Method
Investment - Medivation, Inc. (Details)
63: R47 Acquisitions, Assets and Liabilities Held for HTML 95K
Sale, Licensing Agreements, Research and
Development and Collaborative Arrangements,
Equity-Method Investments and Cost-Method
Investment - Bamboo Therapeutics, Inc. (Details)
64: R48 Acquisitions, Assets and Liabilities Held for HTML 80K
Sale, Licensing Agreements, Research and
Development and Collaborative Arrangements,
Equity-Method Investments and Cost-Method
Investment - Anacor Pharmaceuticals, Inc.
(Details)
65: R49 Acquisitions, Assets and Liabilities Held for HTML 261K
Sale, Licensing Agreements, Research and
Development and Collaborative Arrangements,
Equity-Method Investments and Cost-Method
Investment - Hospira Acquisition (Details)
66: R50 Acquisitions, Assets and Liabilities Held for HTML 94K
Sale, Licensing Agreements, Research and
Development and Collaborative Arrangements,
Equity-Method Investments and Cost-Method
Investment - Additional Acquisitions (Details)
67: R51 Acquisitions, Assets and Liabilities Held for HTML 151K
Sale, Licensing Agreements, Research and
Development and Collaborative Arrangements,
Equity-Method Investments and Cost-Method
Investment - Assets and Liabilities Held for Sale
(Details)
68: R52 Acquisitions, Assets and Liabilities Held for HTML 86K
Sale, Licensing Agreements, Research and
Development and Collaborative Arrangements,
Equity-Method Investments and Cost-Method
Investment - Licensing Agreements (Details)
69: R53 Acquisitions, Assets and Liabilities Held for HTML 153K
Sale, Licensing Agreements, Research and
Development and Collaborative Arrangements,
Equity-Method Investments and Cost-Method
Investment - Research and Development and
Collaborative Arrangements (Detail)
70: R54 Acquisitions, Assets and Liabilities Held for HTML 103K
Sale, Licensing Agreements, Research and
Development and Collaborative Arrangements,
Equity-Method Investments and Cost-Method
Investment - Equity and Cost-Method Investments
(Details)
71: R55 Restructuring Charges and Other Costs Associated HTML 92K
with Acquisitions and Cost-Reduction/Productivity
Initiatives - Narrative (Detail)
72: R56 Restructuring Charges and Other Costs Associated HTML 100K
with Acquisitions and Cost-Reduction/Productivity
Initiatives - Costs (Detail)
73: R57 Restructuring Charges and Other Costs Associated HTML 99K
with Acquisitions and Cost-Reduction/Productivity
Initiatives - Costs - Footnotes (Detail)
74: R58 Restructuring Charges and Other Costs Associated HTML 78K
with Acquisitions and Cost-Reduction/Productivity
Initiatives - Restructuring Accruals (Detail)
75: R59 Restructuring Charges and Other Costs Associated HTML 62K
with Acquisitions and Cost-Reduction/Productivity
Initiatives - Restructuring Accruals - Footnotes
(Detail)
76: R60 Other (Income)/Deductions - Net (Details) HTML 94K
77: R61 Other (Income)/Deductions - Net - Footnotes - HTML 55K
Interest (Income) Expense (Details)
78: R62 Other (Income)/Deductions - Net - Footnotes - HTML 72K
Royalty Income (Details)
79: R63 Other (Income)/Deductions - Net - Footnotes - HTML 75K
Commitments and Contingencies (Details)
80: R64 Other (Income)/Deductions - Net - Footnotes - HTML 78K
Investments (Details)
81: R65 Other (Income)/Deductions - Net - Footnotes - HTML 104K
Indefinite-Lived Intangibles (Details)
82: R66 Other (Income)/Deductions - Net - Footnotes - HTML 58K
Finite-Lived Intangibles (Details)
83: R67 Other (Income)/Deductions - Net - Footnotes - HTML 80K
Additional Information (Details)
84: R68 Other (Income)/Deductions - Net - Additional HTML 92K
Information about Intangible Assets (Detail)
85: R69 Tax Matters - Income from Continuing Operations HTML 63K
Before Provision for Taxes on Income (Details)
86: R70 Tax Matters - Provision for Taxes on Income HTML 83K
(Details)
87: R71 Tax Matters - Provision for Taxes on Income HTML 62K
(Narrative) (Details)
88: R72 Tax Matters - Tax Rate Reconciliation (Details) HTML 81K
89: R73 Tax Matters - Deferred Taxes (Details) HTML 116K
90: R74 Tax Matters - Deferred Taxes - Footnotes (Details) HTML 63K
91: R75 Tax Matters - Narrative (Details) HTML 83K
92: R76 Tax Matters - Reconciliation of Gross Unrecognized HTML 75K
Tax Benefits (Details)
93: R77 Tax Matters - Reconciliation of Gross Unrecognized HTML 70K
Tax Benefits - Footnotes (Details)
94: R78 Tax Matters - Taxes on Items of Other HTML 102K
Comprehensive Income/(Loss) (Details)
95: R79 Accumulated Other Comprehensive Loss, Excluding HTML 81K
Noncontrolling Interests (Details)
96: R80 Accumulated Other Comprehensive Loss, Excluding HTML 56K
Noncontrolling Interests - Footnotes (Details)
97: R81 Accumulated Other Comprehensive Loss, Excluding HTML 61K
Noncontrolling Interests - Narrative (Details)
98: R82 Financial Instruments - Assets and Liabilities HTML 132K
Measured on Recurring Basis (Details)
99: R83 Financial Instruments - Assets and Liabilities HTML 98K
Measured on Recurring Basis - Footnotes (Details)
100: R84 Financial Instruments - Balance Sheet Grouping HTML 82K
(Details)
101: R85 Financial Instruments - Balance Sheet Grouping - HTML 89K
Footnotes (Details)
102: R86 Financial Instruments - Investments in Debt HTML 120K
Securities (Details)
103: R87 Financial Instruments - Narrative (Details) HTML 86K
104: R88 Financial Instruments - Long-Term Debt Narrative HTML 100K
(Details)
105: R89 Financial Instruments - Long-Term Debt (Details) HTML 139K
106: R90 Financial Instruments - Long-Term Debt - Footnotes HTML 70K
(Details)
107: R91 Financial Instruments - Long-Term Debt Outstanding HTML 69K
Maturities (Details)
108: R92 Financial Instruments - Derivative Financial HTML 136K
Instruments and Hedging Activities (Details)
109: R93 Inventories (Details) HTML 76K
110: R94 Property, Plant and Equipment (Details) HTML 99K
111: R95 Identifiable Intangible Assets and Goodwill - HTML 92K
Finite-lived and Indefinite-lived Intangible
Assets (Details)
112: R96 Identifiable Intangible Assets and Goodwill - HTML 68K
Finite-lived Intangible Assets Percentage of Total
Intangibles (Details)
113: R97 Identifiable Intangible Assets and Goodwill - HTML 68K
Indefinite-lived Intangible Assets Percentage of
Total Intangibles (Details)
114: R98 Identifiable Intangible Assets and Goodwill - HTML 65K
Narrative (Details)
115: R99 Identifiable Intangible Assets and Goodwill - HTML 64K
Expected Annual Amortization Expense (Details)
116: R100 Identifiable Intangible Assets and Goodwill - HTML 78K
Goodwill (Details)
117: R101 Pension and Postretirement Benefit Plans and HTML 68K
Defined Contribution Plans - Narrative (Details)
118: R102 Pension and Postretirement Benefit Plans and HTML 149K
Defined Contribution Plans (Details)
119: R103 Pension and Postretirement Benefit Plans and HTML 69K
Defined Contribution Plans - Amounts Expected to
be Amortized into Net Periodic Benefit Costs
(Details)
120: R104 Pension and Postretirement Benefit Plans and HTML 89K
Defined Contribution Plans - Weighted-Average
Actuarial Assumptions (Details)
121: R105 Pension and Postretirement Benefit Plans and HTML 62K
Defined Contribution Plans - Healthcare Cost Trend
Rate Assumptions (Details)
122: R106 Pension and Postretirement Benefit Plans and HTML 64K
Defined Contribution Plans - One-Percentage-Point
Increase or Decrease in the Healthcare Cost Trend
Rate (Details)
123: R107 Pension and Postretirement Benefit Plans and HTML 188K
Defined Contribution Plans - Obligations and
Funded Status (Details)
124: R108 Pension and Postretirement Benefit Plans and HTML 80K
Defined Contribution Plans - Funded Status
Recognized in Consolidated Balance Sheets
(Details)
125: R109 Pension and Postretirement Benefit Plans and HTML 75K
Defined Contribution Plans - Amounts Recognized in
Accumulated Other Comprehensive (Loss)/Income
(Details)
126: R110 Pension and Postretirement Benefit Plans and HTML 64K
Defined Contribution Plans - Amounts Recognized in
Accumulated Other Comprehensive (Loss)/Income -
Footnotes (Details)
127: R111 Pension and Postretirement Benefit Plans and HTML 74K
Defined Contribution Plans - Pension Plans in
Excess of Plan Assets (Details)
128: R112 Pension and Postretirement Benefit Plans and HTML 250K
Defined Contribution Plans - Plan Assets (Details)
129: R113 Pension and Postretirement Benefit Plans and HTML 92K
Defined Contribution Plans - Analysis of Changes
in Significant Investments Valued Using
Significant Unobservable Inputs (Details)
130: R114 Pension and Postretirement Benefit Plans and HTML 128K
Defined Contribution Plans - Long-term Target
Asset Allocations Ranges and the Percentage of the
Fair Value of Plan Assets (Detail)
131: R115 Pension and Postretirement Benefit Plans and HTML 107K
Defined Contribution Plans - Expected Future Cash
Flow Information (Details)
132: R116 Equity - Summary of Common Stock Purchases HTML 64K
(Details)
133: R117 Equity - Narrative (Details) HTML 112K
134: R118 Share-Based Payments - Narrative (Detail) HTML 83K
135: R119 Share-Based Payments - Impact on Net Income HTML 76K
(Detail)
136: R120 Share-Based Payments - Restricted Stock Unit HTML 87K
Activity (Detail)
137: R121 Share-Based Payments - Data Related to All HTML 62K
Restricted Stock Unit Activity (Detail)
138: R122 Share-Based Payments - Stock Option Narrative HTML 62K
(Details)
139: R123 Share-Based Payments - Valuation Assumptions of HTML 67K
Stock Options (Detail)
140: R124 Share-Based Payments - Stock Option Activity HTML 107K
(Detail)
141: R125 Share-Based Payments - Data Related to All Stock HTML 70K
Option Activity (Detail)
142: R126 Share-Based Payments - Portfolio Performance HTML 65K
Shares Narrative (Details)
143: R127 Share-Based Payments - Portfolio Performance HTML 82K
Shares Activity (Details)
144: R128 Share-Based Payments - Data Related to All HTML 62K
Portfolio Performance Shares Activity (Details)
145: R129 Share-Based Payments - Total Shareholder Return HTML 72K
Units Narrative (Details)
146: R130 Share-Based Payments - Valuation Assumptions of HTML 66K
Total Shareholder Return Units (Detail)
147: R131 Share-Based Payments - Total Shareholder Return HTML 91K
Units Activity (Details)
148: R132 Share-Based Payments - Outstanding Total HTML 98K
Shareholder Return Units Activity (Details)
149: R133 Share-Based Payments - Data Related to All Total HTML 62K
Shareholder Return Units (Details)
150: R134 Share-Based Payments - Performance Share Awards HTML 68K
(PSAs) Narrative (Details)
151: R135 Share-Based Payments - Performance Share Awards HTML 77K
(PSAs) Activity (Details)
152: R136 Share-Based Payments - Data Related to All HTML 62K
Performance Share Awards (PSAs) (Details)
153: R137 Earnings Per Common Share Attributable to Pfizer HTML 109K
Inc. Common Shareholders - Basic and Diluted
Numerator and Denominator (Details)
154: R138 Lease Commitments (Detail) HTML 73K
155: R139 Commitments and Contingencies (Action In Which We HTML 97K
Are the Plaintiff) (Details)
156: R140 Commitments and Contingencies (Action In Which We HTML 88K
Are The Defendant) (Details)
157: R141 Commitments and Contingencies (Certain Matters HTML 97K
Resolved And Purchase Commitments) (Details)
158: R142 Segment, Geographic and Other Revenue Information HTML 102K
- Narrative (Detail)
159: R143 Segment, Geographic and Other Revenue Information HTML 99K
(Detail)
160: R144 Segment, Geographic and Other Revenue Information HTML 116K
- Footnotes (Detail)
161: R145 Segment, Geographic and Other Revenue Information HTML 68K
- Revenues By Geographic Area (Detail)
162: R146 Segment, Geographic and Other Revenue Information HTML 63K
- Revenues By Geographic Area - Footnotes (Detail)
163: R147 Segment, Geographic and Other Revenue Information HTML 70K
- Long-Lived Assets By Geographic Region (Detail)
164: R148 Segment, Geographic and Other Revenue Information HTML 246K
- Revenues By Products (Detail)
165: R149 Subsequent Event (Details) HTML 81K
167: XML IDEA XML File -- Filing Summary XML 340K
166: EXCEL IDEA Workbook of Financial Reports XLSX 294K
11: EX-101.INS XBRL Instance -- pfe-20161231 XML 13.92M
13: EX-101.CAL XBRL Calculations -- pfe-20161231_cal XML 579K
14: EX-101.DEF XBRL Definitions -- pfe-20161231_def XML 2.77M
15: EX-101.LAB XBRL Labels -- pfe-20161231_lab XML 4.59M
16: EX-101.PRE XBRL Presentations -- pfe-20161231_pre XML 3.38M
12: EX-101.SCH XBRL Schema -- pfe-20161231 XSD 526K
168: ZIP XBRL Zipped Folder -- 0000078003-17-000014-xbrl Zip 972K
| Exhibit |
Company | Where Incorporated or Organized |
Agouron Pharmaceuticals, LLC | California |
AH Robins LLC | Delaware |
AHP Holdings B.V. | Netherlands |
AHP Manufacturing B.V. | Netherlands |
Alacer
Corp. | California |
Alpharma Holdings Inc. | Delaware |
Alpharma Pharmaceuticals LLC | Delaware |
Alpharma Specialty Pharma Inc. | Delaware |
Alpharma USHP Inc. | Delaware |
American Food Industries LLC | Delaware |
Anacor
IP Holdings, Ltd. | Cayman Islands |
Anacor Pharmaceuticals, Inc. | Delaware |
Ayerst-Wyeth Pharmaceuticals LLC | Delaware |
Bamboo Therapeutics, Inc. | Delaware |
BINESA 2002, S.L. | Spain |
Bioren, LLC | Delaware |
Blue
Whale Re Ltd. | Vermont |
C.E. Commercial Holdings C.V. | Netherlands |
C. E. Commercial Investments C.V. | Netherlands |
C. P. Pharmaceuticals International C.V. | Netherlands |
CICL Corporation | Delaware |
COC I Corporation | Delaware |
Coley
Pharmaceutical GmbH | Germany |
Coley Pharmaceutical Group, Inc. | Delaware |
Continental Pharma, Inc. | Belgium |
Covx Technologies Ireland Limited | Ireland |
Cyanamid de Argentina S.A. | Delaware |
Cyanamid de Colombia, S.A. | Delaware |
Cyanamid
Inter-American Corporation | Delaware |
Distribuidora Mercantil Centro Americana, S.A. | Delaware |
Encysive Pharmaceuticals Inc. | Delaware |
Esperion LUV Development, Inc. | Delaware |
Excaliard Pharmaceuticals, Inc. | Delaware |
Farminova Produtos Farmaceuticos de Inovacao, Lda. | Portugal |
Farmogene
Productos Farmaceuticos Lda | Portugal |
Ferrosan A/S | Denmark |
Ferrosan International A/S | Denmark |
Ferrosan S.R.L. | Romania |
FoldRx Pharmaceuticals, Inc. | Delaware |
Fort Dodge Manufatura Ltda. | Brazil |
G.
D. Searle & Co. Limited | United Kingdom |
G. D. Searle International Capital LLC | Delaware |
G. D. Searle LLC | Delaware |
Genetics Institute, LLC | Delaware |
GenTrac, Inc. | Wisconsin |
GI Europe, Inc. | Delaware |
GI
Japan, Inc. | Delaware |
Greenstone LLC | Delaware |
Haptogen Limited | United Kingdom |
HBAF Ltd. | Bahamas |
Hospira (China) Enterprise Management Co. Ltd. | People's Republic of China |
Hospira Adelaide Pty Ltd | Australia |
Hospira
Argentina S.R.L. | Argentina |
Hospira Aseptic Services Limited | United Kingdom |
Hospira Australia Pty Ltd | Australia |
Hospira Bahamas (Australia) Holdings Ltd. | Bahamas |
Hospira Bahamas (Ireland) Corp. | Bahamas |
Hospira Bahamas Biologics Ltd. | Bahamas |
Hospira
Bahamas International Holdings Ltd. | Bahamas |
Hospira Benelux BVBA | Belgium |
Hospira Boulder, Inc. | Delaware |
Hospira Chile Limitada | Chile |
Hospira Costa Rica Ltd. | Bahamas |
Hospira Deutschland GmbH | Germany |
Hospira
Enterprises B.V. | Netherlands |
Hospira Fleet Services, LLC | Delaware |
Hospira France SAS | France |
Hospira Healthcare B.V. | Netherlands |
Hospira Healthcare Corporation | Canada |
Hospira Healthcare India Private Limited | India |
Hospira
Holding Ltd. | Bahamas |
Hospira Holdings (S.A.) Pty Ltd | Australia |
Hospira Invicta, S.A. | Spain |
Hospira Ireland Holdings Unlimited Company | Ireland |
Hospira Ireland Sales Limited | Ireland |
Hospira Italia S.r.l. | Italy |
Hospira
Japan G.K. | Japan |
Hospira Korea Co. Ltd | Republic of Korea |
Hospira Limitada | Colombia |
Hospira Limited | Hong Kong |
Hospira Ltd. | Bahamas |
Hospira Malaysia Sdn Bhd | Malaysia |
Hospira Nordic AB | Sweden |
Hospira
NZ Limited | New Zealand |
Hospira Peru SRL | Peru |
Hospira Philippines, Inc. | Philippines |
Hospira Portugal LDA | Portugal |
Hospira Productos Farmaceuticos y Hospitalarios, S.L. | Spain |
Hospira Produtos Hospitalares Ltda. | Brazil |
Hospira
Pte. Ltd. | Singapore |
Hospira Pty Limited | Australia |
Hospira Puerto Rico, LLC | Delaware |
Hospira S.p.A. | Italy |
Hospira Singapore Pte Ltd | Singapore |
Hospira UK Limited | United Kingdom |
Hospira
Unlimited Company | Ireland |
Hospira Worldwide, LLC | Delaware |
Hospira Zagreb d.o.o. | Croatia |
Hospira, Inc. | Delaware |
Hospira, S. de R.L. de C.V. | Mexico |
Industrial
Santa Agape, S.A. | Guatemala |
InnoPharma Licensing, LLC | Delaware |
InnoPharma, Inc. | Delaware |
Innovative Drug Delivery Systems, Inc. | Delaware |
International Affiliated Corporation LLC | Delaware |
IP Pharmaceuticals India Private Limited | India |
Javelin
Pharmaceuticals, Inc. | Delaware |
JMI-Daniels Pharmaceuticals, Inc. | Florida |
John Wyeth & Brother Limited | United Kingdom |
Kiinteistö oy Espoon Pellavaniementie 14 | Finland |
King Pharmaceuticals Holdings LLC | Delaware |
King Pharmaceuticals LLC | Delaware |
King
Pharmaceuticals Research and Development, LLC | Delaware |
Korea Pharma Holding Company Limited | Hong Kong |
Laboratoires Pfizer, S.A. | Morocco |
Laboratorios Parke Davis, S.L. | Spain |
Laboratorios Pfizer Ltda. | Brazil |
Laboratórios Pfizer, Lda. | Portugal |
Laboratorios
Wyeth LLC | Pennsylvania |
Laboratorios Wyeth S.A. | Venezuela |
Mayne Pharma IP Holdings (Euro) Pty Ltd | Australia |
Medivation Europe Limited | United Kingdom |
Medivation Field Solutions, Inc. | Delaware |
Medivation International (Bermuda) Ltd. | Bermuda |
Medivation
Neurology, Inc. | Delaware |
Medivation Prostate Therapeutics, Inc. | Delaware |
Medivation Services, Inc. | Delaware |
Medivation Technologies, Inc. | Delaware |
Medivation, Inc. | Delaware |
Meridian Medical Technologies Limited | United Kingdom |
Meridian
Medical Technologies, Inc. | Delaware |
Monarch Pharmaceuticals, LLC | Tennessee |
MPP Trustee Limited | United Kingdom |
MTG Divestitures LLC | Delaware |
Neusentis Limited | United Kingdom |
NextWave Pharmaceuticals Incorporated | Delaware |
PAH
USA IN8 LLC | Delaware |
Parke Davis Limited | Hong Kong |
Parke Davis Productos Farmaceuticos Lda | Portugal |
Parke, Davis & Company LLC | Michigan |
Parkedale Pharmaceuticals, Inc. | Michigan |
Parke-Davis Manufacturing Corp. | Delaware |
P-D
Co., LLC | Delaware |
Peak Enterprises LLC | Delaware |
PEH G.K. | Japan |
PF Americas Holding C.V. | Netherlands |
PF Asia Manufacturing B.V. | Netherlands |
PF PR Holdings C.V. | Netherlands |
PF PRISM C.V. | Netherlands |
PF
PRISM Holdings S.a.r.l. | Luxembourg |
PF Prism S.á.r.l. | Luxembourg |
PFE Holdings G.K. | Japan |
PFE Pfizer Holdings 1 LLC | Delaware |
PFE Pfizer Holdings 2 LLC | Delaware |
PFE
PH 1 LLC | Delaware |
PFE PHAC Holdings 1 LLC | Delaware |
PFE PHAC Inc. | Delaware |
PFE PUC Mexico 1 LLC | Delaware |
PFE PUC Mexico 2 LLC | Delaware |
PFE Wyeth Holdings LLC | Delaware |
PFE Wyeth-Ayerst
(Asia) LLC | Delaware |
Pfizer | France |
Pfizer (China) Research and Development Co. Ltd. | People's Republic of China |
Pfizer (H.K.) Holding Limited | Hong Kong |
Pfizer (Malaysia) Sdn Bhd | Malaysia |
Pfizer (Perth) Pty Limited | Australia |
Pfizer
(Thailand) Limited | Thailand |
Pfizer (Wuhan) Research and Development Co. Ltd. | People's Republic of China |
Pfizer AB | Sweden |
Pfizer Africa & Middle East for Pharmaceuticals, Veterinarian Products & Chemicals S.A.E. | Egypt |
Pfizer Afrique de L'Ouest | Senegal |
Pfizer AG | Switzerland |
Pfizer
Animal Health MA EEIG | United Kingdom |
Pfizer Anti-Infectives AB | Sweden |
Pfizer ApS | Denmark |
Pfizer AS | Norway |
Pfizer Asia Manufacturing Pte. Ltd. | Singapore |
Pfizer Asia Pacific Pte Ltd. | Singapore |
Pfizer
Atlantic Holdings S.a.r.l. | Luxembourg |
Pfizer Australia Holdings B.V. | Netherlands |
Pfizer Australia Holdings Pty Limited | Australia |
Pfizer Australia Investments Pty. Ltd. | Australia |
Pfizer Australia Pty Limited | Australia |
Pfizer B.V. | Netherlands |
Pfizer
Baltic Holdings B.V. | Netherlands |
Pfizer BH D.o.o. | Bosnia and Herzegovina |
Pfizer Biofarmacêutica, Sociedade Unipessoal Lda | Portugal |
Pfizer Biologics (Hangzhou) Co. Ltd | People's Republic of China |
Pfizer Biologics Ireland Holdings Limited | Ireland |
Pfizer Biossimilares Participações Ltda. | Brazil |
Pfizer
Biotech Corporation | Taiwan |
Pfizer Bolivia S.A. | Bolivia |
Pfizer Canada Inc. | Canada |
Pfizer CentreSource Asia Pacific Pte. Ltd. | Singapore |
Pfizer Chile S.A. | Chile |
Pfizer Cia. Ltda. | Ecuador |
Pfizer
Colombia Spinco I LLC | Pennsylvania |
Pfizer Commercial Holdings Coöperatief U.A. | Netherlands |
Pfizer Commercial Holdings TRAE Kft. | Hungary |
Pfizer Commercial TRAE Trading Kft. | Hungary |
Pfizer Consumer Healthcare AB | Sweden |
Pfizer Consumer Healthcare GmbH | Germany |
Pfizer
Consumer Healthcare Ltd. | United Kingdom |
Pfizer Consumer Manufacturing Italy S.r.l. | Italy |
Pfizer Corporation | Panama |
Pfizer Corporation Austria Gesellschaft m.b.H. | Austria |
Pfizer Corporation Hong Kong Limited | Hong
Kong |
Pfizer Costa Rica PFE, Sociedad de Responsabilidad Limitada | Costa Rica |
Pfizer Croatia d.o.o. | Croatia |
Pfizer Deutschland GmbH | Germany |
Pfizer Deutschland PFE Holding GmbH | Germany |
Pfizer Development LP | United Kingdom |
Pfizer Development Services
(UK) Limited | United Kingdom |
Pfizer Domestic Ventures Limited | Jersey |
Pfizer Dominicana, S.R.L | Dominican Republic |
Pfizer East India B.V. | Netherlands |
Pfizer Eastern Investments B.V. | Netherlands |
Pfizer Egypt S.A.E. | Egypt |
Pfizer
Enterprise Holdings B.V. | Netherlands |
Pfizer Enterprises LLC | Delaware |
Pfizer Enterprises SARL | Luxembourg |
Pfizer ESP Pty Ltd | Australia |
Pfizer EU PFE MA EEIG | United Kingdom |
Pfizer Europe Finance B.V. | Netherlands |
Pfizer
Europe Holdings SARL | Luxembourg |
Pfizer Europe MA EEIG | United Kingdom |
Pfizer Export B.V. | Netherlands |
Pfizer Export Company | Ireland |
Pfizer Export Holding Company B.V | Netherlands |
Pfizer Finance Share Service (Dalian) Co., Ltd. | People's Republic of China |
Pfizer
Financial Services N.V./S.A. | Belgium |
Pfizer France International Investments | France |
Pfizer Free Zone Panama, S. de R.L. | Panama |
Pfizer GEP, S.L. | Spain |
Pfizer Germany Partner B.V. | Netherlands |
Pfizer Global Holdings B.V. | Netherlands |
Pfizer
Global Supply Japan Inc. | Japan |
Pfizer Global Trading | Ireland |
Pfizer Group Luxembourg Sarl | Luxembourg |
Pfizer Gulf FZ-LLC | United Arab Emirates |
Pfizer H.C.P. Corporation | New York |
Pfizer Health AB | Sweden |
Pfizer
Health Solutions Inc. | Delaware |
Pfizer Healthcare Ireland | Ireland |
Pfizer Hellas, A.E. | Greece |
Pfizer Himalaya Holdings Coöperatief U.A. | Netherlands |
Pfizer HK Service Company Limited | Hong Kong |
Pfizer Holding France | France |
Pfizer
Holding Ventures | Ireland |
Pfizer Holdings Americas Corporation | Delaware |
Pfizer Holdings Corporation | Delaware |
Pfizer Holdings Europe Unlimited Company | Ireland |
Pfizer Holdings G.K. | Japan |
Pfizer Holdings International Corporation | Delaware |
Pfizer
Holdings International Luxembourg (PHIL) Sarl | Luxembourg |
Pfizer Holdings North America SARL | Luxembourg |
Pfizer Holdings Turkey Limited | Jersey |
Pfizer Hungary Holdings TRAE Kft. | Hungary |
Pfizer Ilaclari Limited Sirketi | Turkey |
Pfizer
Innovations AB | Sweden |
Pfizer Innovations LLC | Russia |
Pfizer Innovative Supply Point International BVBA | Belgium |
Pfizer International Business Europe Unlimited Company | Ireland |
Pfizer International LLC | New York |
Pfizer International Markets Coöperatief U.A. | Netherlands |
Pfizer
International Operations | France |
Pfizer International S. de R.L. | Panama |
Pfizer International Trading (Shanghai) Limited | People's Republic of China |
Pfizer Investment Capital Unlimited Company | Ireland |
Pfizer Investment Co. Ltd. | People's Republic of China |
Pfizer Investment Holdings S.a.r.l. | Luxembourg |
Pfizer
Ireland Investments Limited | Ireland |
Pfizer Ireland Limited | Ireland |
Pfizer Ireland PFE Holding 1 LLC | Delaware |
Pfizer Ireland PFE Holding 2 LLC | Delaware |
Pfizer Ireland Pharmaceuticals | Ireland |
Pfizer Ireland Production Limited | Ireland |
Pfizer
Ireland Ventures Unlimited Company | Ireland |
Pfizer Italia S.r.l. | Italy |
Pfizer Italy Group Holding S.r.l. | Italy |
Pfizer Japan Inc. | Japan |
Pfizer Laboratories (Pty) Limited | South Africa |
Pfizer Laboratories Limited | Kenya |
Pfizer
Laboratories PFE (Pty) Ltd | South Africa |
Pfizer Leasing Ireland Limited | Ireland |
Pfizer Leasing UK Limited | United Kingdom |
Pfizer Limited | India |
Pfizer Limited | Taiwan |
Pfizer Limited | Tanzania |
Pfizer
Limited | Uganda |
Pfizer Limited | United Kingdom |
Pfizer LLC | Russia |
Pfizer Luxco Holdings SARL | Luxembourg |
Pfizer Luxembourg Global Holdings S.à r.l. | Luxembourg |
Pfizer Luxembourg SARL | Luxembourg |
Pfizer
Manufacturing Austria G.m.b.H. | Austria |
Pfizer Manufacturing Belgium N.V. | Belgium |
Pfizer Manufacturing Deutschland GmbH | Germany |
Pfizer Manufacturing Deutschland Grundbesitz GmbH & Co. KG | Germany |
Pfizer Manufacturing Deutschland PFE GmbH | Germany |
Pfizer Manufacturing Holdings LLC | Delaware |
Pfizer
Manufacturing Ireland Unlimited Company | Ireland |
Pfizer Manufacturing LLC | Delaware |
Pfizer Manufacturing Services | Ireland |
Pfizer Medical Technology Group (Belgium) N.V. | Belgium |
Pfizer Medicamentos Genericos e Participacoes Ltda. | Brazil |
Pfizer Mexico Luxco SARL | Luxembourg |
Pfizer
Mexico, S.A. de C.V. | Mexico |
Pfizer Middle East for Pharmaceuticals, Animal Health and Chemicals S.A.E. | Egypt |
Pfizer Namibia (Proprietary) Limited | Namibia |
Pfizer New Zealand Limited | New Zealand |
Pfizer Norge AS | Norway |
Pfizer
North American Holdings Inc. | Delaware |
Pfizer OTC B.V. | Netherlands |
Pfizer Overseas LLC | Delaware |
Pfizer Oy | Finland |
Pfizer Pakistan Limited | Pakistan |
Pfizer Parke Davis | Philippines |
Pfizer
Parke Davis (Thailand) Ltd. | Thailand |
Pfizer Parke Davis Sdn. Bhd. | Malaysia |
Pfizer PFE ApS | Denmark |
Pfizer PFE Argentina Holding 2 B.V. | Netherlands |
Pfizer PFE Argentina Holding B.V. | Netherlands |
Pfizer PFE Asia Pacific Pte. Ltd. | Singapore |
Pfizer
PFE AsiaPac Holding B.V. | Netherlands |
Pfizer PFE Australia Holding B.V. | Netherlands |
Pfizer PFE Australia Pty Ltd | Australia |
Pfizer PFE B.V. | Netherlands |
Pfizer PFE Baltic Holdings B.V. | Netherlands |
Pfizer PFE Belgium SPRL | Belgium |
Pfizer
PFE Brazil Holding S.à r.l. | Luxembourg |
Pfizer PFE Chile Holding LLC | Delaware |
Pfizer PFE CIA. Ltda. | Ecuador |
Pfizer PFE Colombia Holding 2 Corporation | Delaware |
Pfizer PFE Colombia Holding Corp. | Delaware |
Pfizer PFE Colombia S.A.S | Colombia |
Pfizer
PFE Commercial Holdings LLC | Delaware |
Pfizer PFE Croatia Holding B.V. | Netherlands |
Pfizer PFE Eastern Investments B.V. | Netherlands |
Pfizer PFE Finland Oy | Finland |
Pfizer PFE France | France |
Pfizer PFE Global Holdings B.V. | Netherlands |
Pfizer
PFE İlaçları Anonim Şirketi | Turkey |
Pfizer PFE Ireland 1 B.V. | Netherlands |
Pfizer PFE Ireland 2 B.V. | Netherlands |
Pfizer PFE Ireland Pharmaceuticals Holding 1 Coöperatief U.A. | Netherlands |
Pfizer PFE Ireland Pharmaceuticals Holding 2 Coöperatief U.A. | Netherlands |
Pfizer PFE Italy Group Holding Coöperatief
U.A. | Netherlands |
Pfizer PFE Italy Holdco 2 S.à r.l. | Luxembourg |
Pfizer PFE Italy Holdco S.à r.l. | Luxembourg |
Pfizer PFE Korea Holding 1 B.V. | Netherlands |
Pfizer PFE Korea Holding 2 B.V. | Netherlands |
Pfizer PFE Korlátolt Felelősségű Társaság | Hungary |
Pfizer
PFE Limited | Taiwan |
Pfizer PFE Luxembourg S.à r.l. | Luxembourg |
Pfizer PFE Mexico Holding 1 B.V. | Netherlands |
Pfizer PFE Mexico Holding 2 B.V. | Netherlands |
Pfizer PFE Mexico Holding 3 LLC | Delaware |
Pfizer PFE Netherlands Holding 1 C.V. | Netherlands |
Pfizer
PFE New Zealand | New Zealand |
Pfizer PFE New Zealand Holding B.V. | Netherlands |
Pfizer PFE Norway Holding S.à r.l. | Luxembourg |
Pfizer PFE Peru Holding LLC | Delaware |
Pfizer PFE Peru S.R.L. | Peru |
Pfizer
PFE Pharmaceuticals Holding B.V. | Netherlands |
Pfizer PFE Pharmaceuticals Israel Holding LLC | Delaware |
Pfizer PFE Pharmaceuticals Israel Ltd. | Israel |
Pfizer PFE PHIL UAE Holding 2 B.V | Netherlands |
Pfizer PFE PHIL UAE Holding 3 B.V | Netherlands |
Pfizer PFE PHIL UAE Holding 4 B.V. | Netherlands |
Pfizer
PFE Philippines Holding 1 B.V. | Netherlands |
Pfizer PFE Philippines Holding 2 B.V. | Netherlands |
Pfizer PFE PILSA Holdco S.à r.l. | Luxembourg |
Pfizer PFE Poland Holding B.V. | Netherlands |
Pfizer PFE Private Limited | Singapore |
Pfizer PFE S.R.L | Argentina |
Pfizer
PFE Service Company Holding Coöperatief U.A. | Netherlands |
Pfizer PFE Servicios Mexico, S. de R.L. C.V. | Mexico |
Pfizer PFE Singapore Holding Coöperatief U.A. | Netherlands |
Pfizer PFE Singapore Pte. Ltd. | Singapore |
Pfizer PFE South Africa Holding B.V. | Netherlands |
Pfizer PFE Spain B.V. | Netherlands |
Pfizer
PFE Spain Holding, S.L. | Spain |
Pfizer PFE Spain Holdings LLC | Delaware |
Pfizer PFE Sweden Holding 2 S.á.r.l. | Luxembourg |
Pfizer PFE Sweden Holding S.á.r.l. | Luxembourg |
Pfizer PFE Switzerland GmbH | Switzerland |
Pfizer PFE Turkey Holding 1 B.V. | Netherlands |
Pfizer
PFE Turkey Holding 2 B.V. | Netherlands |
Pfizer PFE UK Holding 4 LP | United Kingdom |
Pfizer PFE UK Limited | United Kingdom |
Pfizer PFE US Holdings 1 LLC | Delaware |
Pfizer PFE US Holdings 2 LLC | Delaware |
Pfizer PFE US Holdings 3 LLC | Delaware |
Pfizer
PFE US Holdings 4 LLC | Delaware |
Pfizer PFE US Holdings 5 LLC | Delaware |
Pfizer PFE US Holdings 6 LLC | Delaware |
Pfizer PFE, Inc. | Philippines |
Pfizer PFE, spol. s r.o. | Czech Republic |
Pfizer PGM | France |
Pfizer
PGRD | France |
Pfizer Pharm Algerie | Algeria |
Pfizer Pharma GmbH | Germany |
Pfizer Pharma PFE GmbH | Germany |
Pfizer Pharmaceutical (Wuxi) Co., Ltd. | People's Republic of China |
Pfizer Pharmaceutical Trading Limited Liability Company (a/k/a Pfizer Kft. or Pfizer LLC) | Hungary |
Pfizer
Pharmaceuticals B.V. | Netherlands |
Pfizer Pharmaceuticals Global Coöperatief U.A. | Netherlands |
Pfizer Pharmaceuticals Israel Ltd. | Israel |
Pfizer Pharmaceuticals Korea Limited | Republic of Korea |
Pfizer Pharmaceuticals Limited | Cayman Islands |
Pfizer Pharmaceuticals Limited | Ireland |
Pfizer
Pharmaceuticals LLC | Delaware |
Pfizer Pharmaceuticals Ltd. | People's Republic of China |
Pfizer Pharmaceuticals PFE Korea Limited | Republic of Korea |
Pfizer Pharmaceuticals Tunisie Sarl | Tunisia |
Pfizer Pigments Inc. | Delaware |
Pfizer
Polska Sp. z.o.o. | Poland |
Pfizer Prev - Sociedade de Previdencia Privada | Brazil |
Pfizer Private Limited | Singapore |
Pfizer Production LLC | Delaware |
Pfizer Products Inc. | Connecticut |
Pfizer Products India Private Limited | India |
Pfizer
Research (NC), Inc. | Delaware |
Pfizer Romania SRL | Romania |
Pfizer S.A. | Peru |
Pfizer S.A. (Belgium) | Belgium |
Pfizer S.A.S. | Colombia |
Pfizer S.G.P.S. Lda. | Portugal |
Pfizer S.R.L. | Argentina |
Pfizer
S.r.l. | Italy |
Pfizer Saidal Manufacturing | Algeria |
Pfizer Sales Ireland Limited | Ireland |
Pfizer Santé Familiale | France |
Pfizer Saudi Limited | Saudi Arabia |
Pfizer Seiyaku K.K. | Japan |
Pfizer
Service Company BVBA | Belgium |
Pfizer Service Company Ireland Unlimited Company | Ireland |
Pfizer Services 1 | France |
Pfizer Services LLC | Delaware |
Pfizer Shared Services Unlimited Company | Ireland |
Pfizer Shareholdings Intermediate SARL | Luxembourg |
Pfizer
Singapore Trading Pte. Ltd. | Singapore |
Pfizer Spain Holdings Coöperatief U.A. | Netherlands |
Pfizer Specialities Ghana | Ghana |
Pfizer Specialties Limited | Nigeria |
Pfizer Specialty UK Limited | United Kingdom |
Pfizer Strategic Investment Holdings LLC | Delaware |
Pfizer
Sweden Partnership KB | Sweden |
Pfizer Trading Polska sp.z.o.o. | Poland |
Pfizer TRAE Holdings Kft. | Hungary |
Pfizer Transactions C.V. | Netherlands |
Pfizer Transactions Ireland Unlimited Company | Ireland |
Pfizer Transactions LLC | Delaware |
Pfizer
Transactions Luxembourg SARL | Luxembourg |
Pfizer Transport LLC | Delaware |
Pfizer Tunisie SA | Tunisia |
Pfizer Ukraine LLC | Ukraine |
Pfizer Vaccines LLC | Delaware |
Pfizer Venezuela, S.A. | Venezuela |
Pfizer
Venture Investments LLC | Delaware |
Pfizer Ventures LLC | Delaware |
Pfizer Worldwide Services Unlimited Company | Ireland |
Pfizer Zona Franca PFE Holding LLC | Delaware |
Pfizer Zona Franca, S.A. | Costa Rica |
Pfizer, Inc. | Philippines |
Pfizer,
S.A. | Costa Rica |
Pfizer, S.A. de C.V. | Mexico |
Pfizer, S.L. | Spain |
Pfizer, spol. s r.o. | Czech Republic |
Pharmacia & Upjohn Company LLC | Delaware |
Pharmacia
& Upjohn Company, Inc. | Delaware |
Pharmacia & Upjohn LLC | Delaware |
Pharmacia & Upjohn, S.A. de C.V. | Mexico |
Pharmacia Brasil Ltda. | Brazil |
Pharmacia GmbH | Germany |
Pharmacia Hepar LLC | Delaware |
Pharmacia
Holding AB | Sweden |
Pharmacia Inter-American LLC | Pennsylvania |
Pharmacia International B.V. | Netherlands |
Pharmacia Limited | United Kingdom |
Pharmacia LLC | Delaware |
Pharmacia Nostrum, S.A. | Spain |
PHILCO
Holdings S.à r.l. | Luxembourg |
PHIVCO Corp. | Delaware |
PHIVCO Holdco S.à r.l. | Luxembourg |
PHIVCO Luxembourg S.à r.l. | Luxembourg |
PN Mexico LLC | Delaware |
PowderJect Research Limited | United Kingdom |
PowderJect
Vaccines, Inc. | Delaware |
Productos Farmaceuticos PFE Bolivia S.A. | Bolivia |
PT. Pfizer Indonesia | Indonesia |
PT. Pfizer Parke Davis | Indonesia |
Purepac Pharmaceutical Holdings, Inc. | Delaware |
PZR Ltd. | United Kingdom |
PZR
Property Limited | United Kingdom |
Renrall LLC | Wyoming |
Rinat Neuroscience Corp. | Delaware |
Rivepar | France |
Roerig Produtos Farmaceuticos, Lda. | Portugal |
Roerig S.A. | Chile |
Roerig, S.A. | Venezuela |
Sao
Cristovao Participacoes Ltda. | Brazil |
Searle Laboratorios, Lda. | Portugal |
Servicios P&U, S. de R.L. de C.V. | Mexico |
Shiley LLC | California |
Sinergis Farma-Produtos Farmaceuticos, Lda. | Portugal |
Site Realty, Inc. | Delaware |
Solinor
LLC | Delaware |
Sugen, Inc. | Delaware |
Tabor LLC | Delaware |
The Pfizer Incubator LLC | Delaware |
Thiakis Limited | United Kingdom |
Treerly Health Co., Ltd | People's Republic of China |
Upjohn Laboratorios
Lda. | Portugal |
US Oral Pharmaceuticals Pty Ltd | Australia |
Vesterålens Naturprodukter A/S | Denmark |
Vesterålens Naturprodukter AB | Sweden |
Vesterålens Naturprodukter AS | Norway |
Vesterålens Naturprodukter OY | Finland |
Vicuron
Holdings LLC | Delaware |
Vinci Farma, S.A. | Spain |
Warner Lambert del Uruguay S.A. | Uruguay |
Warner Lambert Ilac Sanayi ve Ticaret Limited Sirketi | Turkey |
Warner-Lambert (Tanzania), Limited | Tanzania |
Warner-Lambert
(Thailand) Limited | Thailand |
Warner-Lambert Company AG | Switzerland |
Warner-Lambert Company LLC | Delaware |
Warner-Lambert Guatemala, Sociedad Anonima | Guatemala |
Warner-Lambert, S.A. | Delaware |
Whitehall International Inc. | New York |
Whitehall
Laboratories Inc. | Delaware |
W-L LLC | Delaware |
Wyeth (Asia) Limited | Delaware |
Wyeth (Thailand) Ltd. | Thailand |
Wyeth AB | Sweden |
Wyeth Advertising Inc. | New York |
Wyeth Ayerst Inc. | Delaware |
Wyeth
Ayerst S.à r.l. | Luxembourg |
Wyeth Consumer Healthcare LLC | Pennsylvania |
Wyeth Europa Limited | United Kingdom |
Wyeth Farma, S.A. | Spain |
Wyeth Holdings LLC | Maine |
Wyeth Industria Farmaceutica Ltda. | Brazil |
Wyeth
KFT. | Hungary |
Wyeth Lederle S.r.l. | Italy |
Wyeth Lederle Vaccines S.A. | Belgium |
Wyeth LLC | Delaware |
Wyeth Pakistan Limited | Pakistan |
Wyeth Pharmaceutical Co., Ltd. | People's Republic of China |
Wyeth
Pharmaceuticals Company | Puerto Rico |
Wyeth Pharmaceuticals FZ-LLC | United Arab Emirates |
Wyeth Pharmaceuticals Inc. | Delaware |
Wyeth Pharmaceuticals India Private Limited | India |
Wyeth Pharmaceuticals Limited | Ireland |
Wyeth Prev-Sociedade de Previdencia Privada | Brazil |
Wyeth
Puerto Rico, Inc. | Puerto Rico |
Wyeth S.A.S | Colombia |
Wyeth Subsidiary Illinois Corporation | Illinois |
Wyeth Whitehall Export GmbH | Austria |
Wyeth Whitehall SARL | Luxembourg |
Wyeth-Ayerst (Asia) Limited | Delaware |
Wyeth-Ayerst
International LLC | Delaware |
Wyeth-Ayerst Promotions Limited | Delaware |
Yusafarm D.O.O. | Serbia |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 2/23/17 | 3, 4, 8-K | ||
| For Period end: | 12/31/16 | 11-K, 4, 5, SD | ||
| List all Filings | ||||